An MHRA Perspective on the Evolving Regulatory Landscape for Advanced Gene & Genetic Therapies
2:45 pm - Thursday 7th May 2026
- Understanding emerging regulatory frameworks for genome editing products and their unique analytical burdens
- Reviewing regulatory priorities and recent developments across ATMPs
- Exploring the latest advances in regulatory thinking for rare and ultra-rare disease therapies, including how risk-benefit, evidentiary expectations and analytical robustness are assessed when patient populations are small
